青蒿素及其衍生物抗头颈癌作用研究进展

梁毅舟; 农晓琳

doi:10.13201/j.issn.1001-1781.2018.19.021

青蒿素及其衍生物抗头颈癌作用研究进展

梁毅舟,
农晓琳^,

- 广西医科大学口腔医学院口腔颌面外科广西口腔颌面修复与重建研究自治区级重点实验室广西颅颌面畸形临床医学研究中心颌面外科疾病诊治研究重点实验室(广西高校重点实验室) (南宁, 530021)
基金项目:
国家自然科学基金项目 (No:81360404)

广西自然科学基金面上项目 (No:2013GXNSFAA019231)

详细信息

通讯作者: 农晓琳, E-mail:xnong@gxmu.edu.cn

中图分类号: R739.91

收稿日期: 2018-05-04

Progress in the study of artemisinin and its derivatives against head and neck cancer

More Information

Corresponding author: , E-mail: xnong@gxmu.edu.cn

Received Date: 04 May 2018

摘要

- 头颈部肿瘤 /
- 青蒿素 /
- 青蒿素衍生物 /
- 作用机制
Abstract: The head and neck cancer is one of the most common malignant tumors in the world.There are more than 600 000 new cases in the world every year.Cisplatin is often used in the treatment of head and neck cancer at present.However, because of its side effects and drug resistance, cisplatin often failed in the treatment of head and neck cancer.Artemisinin and its derivatives as first-line antimalarial drugs have the advantages of high efficiency, low toxicity and so on.Further study found that artemisinin and its derivatives had cytotoxic effects against head and neck cancer through inducing cell cycle arrest, inducing tumor cell apoptosis and inhibiting cell invasion and migration, oxidative damage, blocking the cell signal transduction and inhibiting angiogenesis.Studying the anti-tumor effects of artemisinin and its derivatives allows for development of safer and more effective antitumor drugs and pain-reduction caused by diseases and traditional treatment, then improve the survival rate and life quality of patients with head and neck cancer.This article reviews the progress in the study of artemisinin and its derivatives in the treatment of head and neck cancer.
- head and neck neoplasms /
- artemisinin /
- artemisinin derivatives /
- mechanism of action

HTML全文

参考文献(33)

[1]	CHEN R Y, LIN Y C, SHEN W C, et al.Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck[J].Sci Rep, 2018, 8:105-105.
[2]	HUANG D, QIU Y, LI G, et al.KDM5 Boverexpression predicts a poor prognosis in patients with squamous cell carcinoma of the head and neck[J].JCancer, 2018, 9:198-204.
[3]	ADACHI M, CUI C, DODGE C T, et al.Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma[J].Oral Oncol, 2012, 48:1220-1226.
[4]	O'NEILL P M, POSNER G H.A medicinal chemistry perspective on artemisinin and related endoperoxides[J].J Med Chem, 2004, 47:2945-2964.
[5]	EFFERTH T.From ancient herb to modern drug:Artemisia annua and artemisinin for cancer therapy[J].Semin Cancer Biol, 2017, 46:65-83.
[6]	JIA L, SONG Q, ZHOU C, et al.Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling[J].PLoS One, 2016, 11:e0147157.
[7]	黄振河, 张月飞, 蒋东辉, 等.双氢青蒿素诱导鼻咽癌CNE-2细胞凋亡及其机制[J].临床耳鼻咽喉头颈外科杂志, 2013, 27 (13):717-720.
[8]	HUANG Z, HUANG X, JIANG D, et al.Dihydroartemisinin inhibits cell proliferation by induced G1 arrest and apoptosis in human nasopharyngeal carcinoma cells[J].J Cancer Res Ther, 2016, 12:244-247.
[9]	ROH J L, KIM E H, JANG H, et al.Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis[J].Redox Biol, 2017, 11:254-262.
[10]	LI Q, NI W, DENG Z, et al.Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress[J].Fundam Clin Pharmacol, 2017, 31:301-310.
[11]	LIN R, ZHANG Z, CHEN L, et al.Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neckcarcinoma cells[J].Cancer Lett, 2016, 381:165-175.
[12]	EFFERTH T.Mechanistic perspectives for 1, 2, 4-trioxanes in anti-cancer therapy[J].Drug Resist Updat, 2005, 8:85-97.
[13]	EFFERTH T, GIAISI M, MERLING A, et al.Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells[J].PLoS One, 2007, 2:e693.
[14]	SIEBER S, GDYNIA G, ROTH W, et al.Combination treatment of malignant B cells using the anti CD20 antibody rituximab and the anti-malarial artesunate[J].Int J Oncol, 2009, 35:149-158.
[15]	HAMACHER-BRADY A, STEIN H A, TUR-SCHNER S, et al.Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production[J].J Biol Chem, 2011, 286:6587-6601.
[16]	POUPEL F, AGHAEI M, MOVAHEDIAN A, et al.Dihydroartemisinin Induces Apoptosis in Human Bladder Cancer Cell Lines Through Reactive Oxygen Species, Mitochondrial Membrane Potential, and Cytochrome C Pathway[J].Int J Prev Med, 2017, 8:78-78.
[17]	LANGFORD M P, MCGEE D J, TA K H, et al.Multiple caspases mediate acute renal cell apoptosis induced by bacterial cell wall components[J].Ren Fail, 2011, 33:192-206.
[18]	HWANG Y P, YUN H J, KIM H G, et al.Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms[J].Biochem Pharmacol, 2010, 79:1714-1726.
[19]	OLLIARO P L, HAYNES R K, MEUNIER B, et al.Possible modes of action of the artemisinin-type compounds[J].Trends Parasitol, 2001, 17:122-126.
[20]	VANDEWYNCKEL Y P, LAUKENS D, GEERTSA, et al.Therapeutic effects of artesunate in hepatocellular carcinoma:repurposing an ancient antimalarial agent[J].Eur J Gastroenterol Hepatol, 2014, 26:861-870.
[21]	MERCER A E, MAGGS J L, SUN X M, et al.Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds[J].J Biol Chem, 2007, 282:9372-9382.
[22]	DROSE S, BRANDT U.The mechanism of mitochondrial superoxide production by the cytochrome bc1 complex[J].J Biol Chem, 2008, 283:21649-21654.
[23]	POURAHMAD J, MORTADA Y, ESKANDARI MR, et al.Involvement of Lysosomal Labilisation and Lysosomal/mitochondrial Cross-Talk in Diclofenac Induced Hepatotoxicity[J].Iran J Pharm Res, 2011, 10:877-887.
[24]	HAMACHER-BRADY A, STEIN H A, TUR-SCHNER S, et al.Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomalreactive oxygen species production[J].J Biol Chem, 2011, 286:6587-6601.
[25]	LIU Y, WANG W, XU L, et al.Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling[J].Oncol Rep, 2013, 30:1723-1730.
[26]	DRENBERG C D, BUABOONNAM J, ORWICK SJ, et al.Evaluation of artemisinins for the treatment of acute myeloid leukemia[J].Cancer Chemother Pharmacol, 2016, 77:1231-1143.
[27]	DA SILVA C G, JARZYNA R, SPECHT A, et al.Extracellular nucleotides and adenosine independently activate AMP-activated protein kinase in endothelial cells:involvement of P2 receptors and adenosine transporters[J].Circ Res, 2006, 98:e39-47.
[28]	KOWSHIK J, BABA A B, GIRI H, et al.Astaxanthin inhibits JAK/STAT-3signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer[J].PLoS One, 2014, 9:e109114.
[29]	CARMELIET P, JAIN R K.Molecular mechanisms and clinical applications of angiogenesis[J].Nature, 2011, 473:298-307.
[30]	DELL'EVA R, PFEFFER U, VENR, et al.Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate[J].Biochem Pharmacol, 2004, 68:2359-2366.
[31]	VANDEWYNCKEL Y P, LAUKENS D, GEERTSA, et al.Therapeutic effects of artesunate in hepatocellular carcinoma:repurposing an ancient antimalarial agent[J].Eur J Gastroenterol Hepatol, 2014, 26:861-870.
[32]	PETRAS J M, YOUNG G D, BAUMAN R A, et al.Arteether-induced brain injury in Macaca mulatta.I.The precerebellar nuclei:the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei[J].Anat Embryol (Berl), 2000, 201:383-397.
[33]	D'ALESSANDRO S, GELATI M, BASILICO N, et al.Differential effects on angiogenesis of two antimalarial compounds, dihydroartemisinin and artemisone:implications for embryotoxicity[J].Toxicology, 2007, 241:66-74.